The absence of a specific antiviral treatment for the highly virulent and lethal coronavirus disease 2019 (Covid-19) remains a significant challenge. The potential of natural agents with immune-promotion capabilities, including apitherapy products, is being investigated as a potential therapeutic modality. Propolis is characterized by a high concentration of bioactive compounds, which exhibit significant antimicrobial, bactericidal, antiviral, anti-inflammatory, immunomodulatory, and antioxidant properties. This study investigated the potential of ethanolic extracts of Brazilian green propolis for COVID-19 treatment. Propolis extracts were obtained at room (EEPV-F) and under 70 °C-heat (EEPV-Q) temperatures, and the extraction yields were 36.74% and 53.54%, respectively. Total flavonoid contents (10.6 ± 0.9 and 6.6 ± 0.2 mg QE g–1), total phenolic compounds (44 ± 2 and 66 ± 3 mg GAE g–1), and antioxidant capacity by DPPH (IC50 values of 18.0 ± 0.3 and 16.6 ± 0.5 μg mL–1) and ABTS (IC50 values of 16.6 ± 0.02 and 15.3 ± 0.2 μg mL–1) assays were determined. The extracts were not cytotoxic to RAW 264.7 macrophages and exhibited dose-dependent anti-inflammatory activity, particularly EEPV-Q. All EEPV-Q concentrations significantly reduced nitric oxide production and demonstrated suitability for further investigation. Molecular docking analysis revealed that the compound guibourtinidol-(4alpha→8)-epiafzelechin exhibited stronger binding affinity for PLpro, RdRp, and Spike-analyzed enzymes. Both EEPV-F and EEPV-Q presented hemolytic activity below 5% across all tested concentrations. Given the limited therapeutic options available for COVID-19, the utilization of green propolis as a therapeutic agent has emerged as a promising and relevant approach. This natural product possesses several advantages, including its safety, ease of oral administration, and its availability as both a natural supplement and a functional food.
An In Silico Investigation of Brazilian Green Propolis Extracts as Potential Treatment for COVID-19
Jeronimo Geraldo Ferreira Júnior,J. Seibert,Viviane Martins Rebello dos Santos,Lucas Resende Dutra Sousa,Tatiane Roquete Amparo,T. M. Valverde,Vagner Rodrigues Santos,Junnia Alvarenga de Carvalho Oliveira,Paula Melo de Abreu Vieira,Vagner de Oliveira Machado,Â. L. Andrade
Published 2025 in ACS Omega
ABSTRACT
PUBLICATION RECORD
- Publication year
2025
- Venue
ACS Omega
- Publication date
2025-08-05
- Fields of study
Medicine, Chemistry, Environmental Science
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-74 of 74 references · Page 1 of 1
CITED BY
- No citing papers are available for this paper.
Showing 0-0 of 0 citing papers · Page 1 of 1